Read More

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho bullish with Buy rating, $34 price target. ELVN's trading value suggests conservative estimation compared to CML market potential.

ELVN

Read More

Alkermes’ Sleeping Disorder Studies’ Data Look Excellent, Analyst Says

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

ALKS

Read More

Goldman Sachs Is Incrementally More Positive On Molson Coors & Constellation Brands: Here’s Why

Goldman Sachs analyst Bonnie Herzog is incrementally more positive on Molson Coors Beverage & Constellation Brands but incrementally negative on Boston Beer Company based on feedback from the beer distributor contacts in the recent Beverage Bytes survey.

SAM

Read More

Charting New Waters: Norwegian Cruise Line Unveils Ambitious Plans For Eight Ships

Norwegian Cruise Line Holdings unveils plans for eight new vessels, expanding its fleet with nearly 25,000 additional berths across three brands. The company also initiates construction of a multi-ship pier at Great Stirrup Cay, enhancing its Caribbean port infrastructure.

NCLH